Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | Overcoming barriers in treating melanoma brain metastases

Brain metastases remain a major hurdle in optimizing patient outcomes in melanoma and current checkpoint inhibitors such as ipilimumab and nivolumab as well as targeted therapies have limited efficacy in the brain. Bently Doonan, MD, University of Florida, Gainesville, FL, discusses strategies to target melanoma brain metastases. Treating brain metastases remain an unmet need, where they can materialize even during melanoma treatment. Whilst surgery and stereotactic radiotherapy are options, novel treatment strategies are required. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.